Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 294, Issue 1, 2007, Pages

  Camilleri, Michael ^a,c   Carlson, Paula ^a   McKinzie, Sanna ^a   Grudell, April ^a   Busciglio, Irene ^a   Burton, Duane ^a   Baxter, Kari ^a   Ryks, Michael ^a   Zinsmeister, Alan R ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b Mayo Clinic   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Fatty acid amide hydrolase; Rectal sensation; Transit anandamide

Indexed keywords

ANANDAMIDE; ENDOCANNABINOID; FATTY ACID AMIDASE;

ABDOMINAL PAIN; ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DYSPEPSIA; FAAH GENE; FEMALE; GASTROINTESTINAL MOTILITY; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTESTINE TRANSIT TIME; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RECTUM MOTILITY; SENSATION; STOMACH EMPTYING;

ADULT; AMIDOHYDROLASES; ENDOCANNABINOIDS; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; QUESTIONNAIRES; RECTUM; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SENSATION; SENSORY THRESHOLDS; SEVERITY OF ILLNESS INDEX;

EID: 38349188452     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00371.2007     Document Type: Article

References (41)

1. Andresen V, Camilleri M, Kim HJ, Stephens DA, Carlson PJ, Talley NJ, Saito YA, Urrutia R, Zinsmeister AR. Is there an association between GNβ3 C825T genotype and lower functional gastrointestinal disorders? Gastroenterology 130: 1985-1994, 2006.
2. Ballon N, Leroy S, Roy C, Bourdel MC, Charles-Nicolas A, Krebs MO, Poirier MF. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J 6: 126-130, 2006.
3. Barrero FJ, Ampuero I, Morales B, Vives F, de Dios Luna Del Castillo J, Hoenicka J, Garcia Yebenes J. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J 5: 135-141, 2005.
4. Bouras EP, Delgado-Aros S, Camilleri M, Castillo EJ, Burton DD, Thomforde GM, Chial HJ. SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut 51: 781-786, 2002.
5. Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med 38: 1807-1810, 1997.
6. Camilleri M. Editorial: Mechanisms in IBS: something old, something new, something borrowed. . . . Neurogastroenterol Motil 17: 311-316, 2005.
7. Camilleri CE, Carlson PJ, Camilleri M, Castillo EJ, Locke GR III, Geno DM, Stephens DA, Zinsmeister AR, Urrutia R. A study of candidate genotypes associated with dyspepsia in a U. S. community. Am J Gastroenterol 101: 581-592, 2006.
8. Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. Gastroenterology 103: 36-42, 1992.
9. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103: 7895-7900, 2006.
10. Castillo EJ, Camilleri M, Locke GR III, Burton DD, Stephens DA, Geno DM, Zinsmeister AR. A community based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol 2: 985-996, 2004.
11. Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet 13: 2113-2119, 2004.
12. Comings DE, Muhleman D, Gade R, Johnson P, Verde R, Saucier G, MacMurray J. Cannabinoid receptor gene (CNR1): association with i. v. drug use. Mol Psychiatry 2: 161-168, 1997.
13. Cremonini F, Houghton LA, Camilleri M, Ferber I, Fell C, Cox V, Castillo EJ, Alpers DH, Dewit OE, Gray E, Lea R, Zinsmeister AR, Whorwell PJ. Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility. Neurogastroenterol Motil 17: 810-820, 2005.
14. Cremonini F, Mullan BP, Camilleri M, Burton DD, Rank MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 16: 1781-1790, 2002.
15. Derogatis LR, Rickels K, Rock A. The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br J Psychiatry 128: 280-290, 1976.
16. 15a. Drossman DA, Corazziari E, Talley NJ, Thompson WA, Whitehead WE (editors). Rome II: The Functional Gastrointestinal Disorders (2nd ed.). Lawrence, KS: Allen, 2000.
17. Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol 293: G137-G145, 2007.
18. Esfandyari T, Camilleri M, Ferber I, Burton D, Baxter K, Zinsmeister AR. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil 18: 831-838, 2006.
19. Flanagan JM, Gerber AL, Cadet JL, Beutler E, Sipe JC. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet 120: 581-588, 2006.
20. Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I, Freund TF. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12: 3239-3249, 2000.
21. Hammer HF, Phillips SF, Camilleri M, Hanson RB. Rectal tone, distensibility, and perception: reproducibility and response to different distensions. Am J Physiol Gastrointest Liver Physiol 274: G584-G590, 1998.
22. Hinds NM, Ullrich K, Smid SD. Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br J Pharmacol 148: 191-199, 2006.
23. Hoffman AF, Lupica CR. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci 20: 2470-2479, 2000.
24. Reference SNP (ref SNP) cluster report: rs324420. http://www.ncbi.nlm. nih.gov/SNP/snp_ref.cgi?rs=324420.
25. 2 adrenoceptor and serotonin-transporter polymorphisms associated with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 53: 829-837, 2004.
26. Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 291: G364-G371, 2006.
27. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5: 400-411, 2005.
28. Kuiken SD, Samsom M, Camilleri M, Mullan BP, Burton DD, Kost LJ, Hardyman TJ, Brinkmann BH, O'Connor MK. Development of a test to measure gastric accommodation in humans. Am J Physiol Gastrointest Liver Physiol 277: G1217-G1221, 1999.
29. Martinez-Gras I, Hoenicka J, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Perez-Hernandez E, Ampuero I, Ramos-Atance JA, Palomo T, Rubio G. (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur Arch Psychiatry Clin Neurosci 256: 437-441, 2006.
30. O'Connor MK, O'Connell R, Keane FB, Byrne PJ, Hennessy TP. The relationship between technetium 99m pertechnetate gastric scanning and gastric contents. Br J Radiol 56: 817-822, 1983.
31. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462, 2006.
32. Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K, Brown DR, Mascolo N, Di Marzo V, Capasso F. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123: 227-234, 2002.
33. Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 18: 949-956, 2006.
34. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 99: 8394-8399, 2002.
35. Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes (Lond) 29: 755-759, 2005.
36. Tsai SJ, Wang YC, Hong CJ. Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatr Genet 10: 149-151, 2000.
37. Vaughan CW, McGregor IS, Christie MJ. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol 127: 935-940, 1999.
38. Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol 141: 775-785, 2004.
39. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 296: 678-682, 2002.
40. Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129: 437-453, 2005.
41. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 67: 361-370, 1983.